



(11)

EP 3 585 892 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
13.07.2022 Bulletin 2022/28

(45) Date of publication and mention
of the grant of the patent:
01.06.2022 Bulletin 2022/22

(21) Application number: **18711737.9**

(22) Date of filing: **27.02.2018**

(51) International Patent Classification (IPC):
C12N 15/10^(2006.01) C07H 1/06^(2006.01)
C12P 19/34^(2006.01)

(52) Cooperative Patent Classification (CPC):
C07H 21/04; C12N 15/1006; C12N 15/1017;
C12Y 201/03003

(86) International application number:
PCT/US2018/019978

(87) International publication number:
WO 2018/157141 (30.08.2018 Gazette 2018/35)

(54) **METHODS FOR PURIFICATION OF MESSENGER RNA**

VERFAHREN ZUR REINIGUNG VON MESSENGER-RNA

PROCÉDÉS DE PURIFICATION D'ARN MESSENGER

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD TN

(30) Priority: **27.02.2017 US 201762463981 P**

(43) Date of publication of application:
01.01.2020 Bulletin 2020/01

(60) Divisional application:
22151272.6 / 4 008 783

(73) Proprietor: **Translate Bio, Inc.**
Waltham, MA 02451 (US)

(72) Inventors:
• **DEROSA, Frank**
Lexington, MA 02421 (US)
• **HEARTLEIN, Michael**
Lexington, MA 02421 (US)
• **ABYSALH, Jonathan**
Lexington, MA 02421 (US)

• **KARVE, Shrirang**
Lexington, MA 02421 (US)
• **DIAS, Anusha**
Lexington, MA 02421 (US)
• **CRAWFORD, Daniel**
Lexington, MA 02421 (US)

(74) Representative: **Elkington and Fife LLP**
Thavies Inn House
3-4 Holborn Circus
London EC1N 2HA (GB)

(56) References cited:
WO-A1-2014/144767 WO-A1-2015/164773
WO-A1-2016/193206

• **KATALIN KARIKÓ ET AL: "Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, GB, vol. 39, no. 21, 1 November 2011 (2011-11-01), pages e142-1, XP002696190, ISSN: 1362-4962, DOI: 10.1093/NAR/GKR695 [retrieved on 2011-09-02]**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 585 892 B8

- **UGUR SAHIN ET AL: "mRNA-based therapeutics - developing a new class of drugs", NATURE REVIEWS DRUG DISCOVERY, vol. 13, no. 10, 19 September 2014 (2014-09-19), pages 759-780, XP055159205, ISSN: 1474-1776, DOI: 10.1038/nrd4278**